A Retrospective Study of Clinical and Genetic Features in a Long-Term Cohort of Mexican Children with Alagille Syndrome
Authors:
- Rodrigo Vázquez-FriasRodrigo Vázquez-Frias
- Gustavo Varela-FascinettoGVGustavo Varela-Fascinetto
- Carlos Patricio Acosta-Rodríguez-BuenoCACarlos Patricio Acosta-Rodríguez-Bueno
- Alejandra ConsueloACAlejandra Consuelo
- Ariel CarrilloACAriel Carrillo
- Magali Reyes-ApodacaMRMagali Reyes-Apodaca
- Rodrigo Moreno-SalgadoRodrigo Moreno-Salgado
- Jaime López-ValdezJLJaime López-Valdez
- Elizabeth Hernández-ChávezEHElizabeth Hernández-Chávez
- Beatriz González-OrtizBGBeatriz González-Ortiz
- José F Cadena-LeónJCJosé F Cadena-León
- Salvador Villalpando-CarriónSalvador Villalpando-Carrión
Open Access
- 6 August 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7626
Abstract
Alagille syndrome (ALGS) is a multisystem disorder characterized by a paucity of intrahepatic bile ducts and cholestasis, often requiring liver transplantation before adulthood. Due to the lack of genotype–phenotype correlation, case series are essential to understand disease presentation and prognosis. Data on Mexican ALGS patients are limited. Therefore, we aimed to characterize a large series of Mexican patients by consolidating cases from major institutions and independent geneticists, with the goal of generating one of the most comprehensive cohorts in Latin America. We retrospectively analyzed clinical records of pediatric ALGS patients, focusing on demographics, clinical features, laboratory and imaging results, biopsy findings, and transplant status. Genetic testing was performed for all cases without prior molecular confirmation. We identified 52 ALGS cases over 13 years; 22 had available clinical records. Of these, only 6 had molecular confirmation at study onset, prompting genetic testing in the remaining 16. We identified six novel JAG1 variants and several previously unreported phenotypic features. A liver transplantation rate of 13% was observed in the cohort. This study represents the largest molecularly confirmed ALGS cohort in Mexico to date. Novel genetic and clinical findings expand the known spectrum of ALGS and emphasize the need for improved therapies, such as IBAT inhibitors, which may alleviate symptoms and reduce the need for transplantation.Keywords
Funding Information
- Biopas Mexico
This publication has 40 references indexed in Scilit:
- First year results and insights from the Mexican Rare Disease Patient RegistryRare, 2024
- Management of adults with Alagille syndromeHepatology International, 2023
- Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA studyHepatology, 2022
- Notch signaling in reproductionTrends in Endocrinology & Metabolism, 2021
- Alagille syndrome mutation update: Comprehensive overview ofJAG1andNOTCH2mutation frequencies and insight into missense variant classificationHuman Mutation, 2019
- A review of syndromes associated with blue sclera, with inclusion of malformations of the head and neckOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2018
- Clinical Features and Genetic Analysis of Pediatric Patients with Alagille Syndrome Presenting Initially with Liver Function AbnormalitiesCurrent Medical Science, 2018
- Polymorphism analysis and new JAG1 gene mutations of Alagille syndrome in Mexican populationMeta Gene, 2014
- A 8.26 Mb deletion in 6q16 and a 4.95 Mb deletion in 20p12 including JAG1 and BMP2 in a patient with Alagille syndrome and Wolff–Parkinson–White syndromeEuropean Journal of Medical Genetics, 2008
- Jagged1 mutations in Alagille syndromeHuman Mutation, 2000